Search This Blog

Thursday, April 25, 2019

Seattle Genetics reports Q1 EPS (8c), consensus (29c)

Reports Q1 revenue $195.2M, consensus $186.77M. As of March 31, 2019, cash and investments were $418.3 million. In addition, the company held stock investments, primarily in Immunomedics common stock, valued at $151.9 million.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)